

AMENDMENTS TO THE CLAIMS

Please cancel, without prejudice, claims 1-10 and 15-21 as presented in the underlying International Application No. PCT/SI2004/000019 as amended by the First Preliminary Amendment dated October 10, 2005.


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:


Claims 1-10 (Cancelled)

Claim 11 (Currently amended): A process for the preparation of amorphous atorvastatin calcium which comprises: a) preparation-provision of a neutral reaction mixture containing a sodium salt of atorvastatin and a nonhydroxylic organic solvent; b) addition of non-cyclic chlorinated organic solvent selected from the group consisting of dichloromethane, trichloroethane, tetrachloroethane and chloroform, or addition of cyclic hydrocarbon solvent selected from the group consisting of cyclohexane, cyclopentane, and methyl cyclohexane to provide a mixture of organic solvents; c) addition of an equivalent or an excess quantity of a source of calcium ions source selected from the group consisting of calcium acetate and calcium chloride thereby forming an aqueous and an organic phase; and, d) isolation of amorphous atorvastatin calcium from an organic phase comprising the organic phase of the mixture of organic solvents.

Claim 12 (Currently amended): The A-process for the preparation of amorphous atorvastatin calcium according to recited in claim 11, wherein the neutral reaction mixture comprising atorvastatin- a sodium salt of atorvastatin and a nonhydroxylic organic solvent is prepared by a process which comprises: a) dissolving a compound of formula I or II:



wherein R₁ and R₂ may independently represent hydrogen, alkyl with one to three carbon atoms, phenyl, or R₁ in R₂ are taken together as (-CH₂)_n-, wherein n may be 4 or 5; R₃ may represent straight or branched chain alkyl of from one to eight carbon atoms or cycloalkyl of from three to six carbon atoms group -0-R₃ may be substituted by the group with the formula:



wherein R₄ and R₅ may independently represent alkyl with one to ten carbon atoms, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, benzyl or phenyl, or R₄ in R₅ are taken together to form:
-(CH₂)₄-, -(CH₂)₅-, -(CH(R⁶)-CH₂)₃-, (CH(R⁶)-CH₂)₄-, -(CH(R⁶)-(CH₂)₂-CH(R⁶))-,
-(CH(R⁶)-(CH₂)₃-, CH(R⁶))-, -CH₂-CH₂-O-CH₂-CH₂-, -CH(R⁶)-CH₂-O-CH₂-CH₂-,
CH(R⁶)-CH₂-O-CH₂-CH₂ (R⁶)-, wherein R⁶ represents alkyl with one to four carbon atoms, in at the
non-hydroxylic organic solvent; and b) preparing forming the sodium salt of atorvastatin under
neutral pH conditions in a neutral reaction mixture comprising said nonhydroxylic organic solvent.

Claim 13 (Previously presented): A process for the preparation of amorphous atorvastatin calcium according to claim 12, wherein the non-hydroxylic organic solvent is tetrahydrofuran.

Claim 14 (Currently amended): A process for the preparation of amorphous atorvastatin calcium according to claim 11, wherein the neutral reaction mixture comprising containing a sodium salt of atorvastatin and a nonhydroxylic organic solvent has shows a pH between 6.5 and 8.0.

Claims 15-21 (Cancelled)

Claim 22 (Currently amended): A process for the preparation of amorphous atorvastatin calcium according to claim 11, wherein the chlorinated organic solvent or the cyclic hydrocarbon solvent is added in a onefold to fivefold quantity based on with respect to the existing volume of the solution.

Claim 23 (Currently amended): A process for the preparation of amorphous atorvastatin calcium according to claim 11, further comprising wherein adding simultaneously with ~~an~~ the addition of the non-cyclic chlorinated organic solvent or the cyclic hydrocarbon solvent also-a 0.5 fold to a twofold quantity of saturated aqueous solution of sodium chloride based on with respect to the existing volume of solutionis added.

Claim 24 (Currently amended): A process for the preparation of amorphous atorvastatin calcium according to claim 11, wherein the isolation of amorphous atorvastatin calcium comprises an addition of a solvent in which atorvastatin calcium is not~~poorly~~ soluble or is poorly soluble.

Claim 25 (Currently amended): A process for the preparation of amorphous atorvastatin calcium according to claim 24, wherein the solvent in which atorvastatin calcium is poorly~~not~~ soluble or is poorly soluble; is ether.

Claim 26 (Currently amended): A process for the preparation of amorphous atorvastatin calcium according to claim 25, wherein the solvent in which atorvastatin calcium is poorly~~not~~ soluble or is poorly soluble; is diisopropylether.

Claim 27 (Currently amended): A process for the preparation of amorphous atorvastatin calcium according to claim 11, wherein the isolation of amorphous atorvastatin calcium comprises:
a) adding a solvent in which atorvastatin calcium is well-soluble, b) concentrating the resulting atorvastatin calcium preparation obtained mixture, c) adding a solvent in which atorvastatin calcium

is poorly-not soluble or is poorly soluble, and d) obtaining a precipitant which is in amorphous form wherein amorphous atorvastatin calcium separates from the reaction mixture.

Claim 28 (Currently amended): A process for the preparation of amorphous atorvastatin calcium according to claim 27, wherein the solvent in which atorvastatin calcium is well-soluble is selected from the group consisting of methanol, ethanol, and propanol.

Claim 29 (Currently amended): A process for the preparation of amorphous atorvastatin calcium according to claim 28, wherein the solvent in which atorvastatin calcium is well-soluble is methanol.

Claim 30 (Currently amended): A process for the preparation of amorphous atorvastatin calcium according to claim 27, wherein the solvent in which atorvastatin calcium is poorly-not soluble or is poorly soluble is ether.

Claim 31 (Currently amended): A process for the preparation of amorphous atorvastatin calcium according to claim 30, wherein the solvent in which atorvastatin calcium is poorly-not soluble or is poorly soluble is diisopropylether.

Claim 32 (Currently amended) A method for the treatment of diseases selected from the group consisting of dyslipidemia, hyperlipidemia, hypercholesterolemia, atherosclerosis, arteriosclerosis, cardiovascular diseases, coronary arterial diseases, coronary heart diseases, disorders of blood circulation, inflammation diseases, bone diseases, disorders of processing beta amyloid precursor protein, said method comprising administering amorphous atorvastatin calcium which is prepared according to the process of claim 11.

Claim 33 (Currently amended) A pharmaceutical composition comprising amorphous atorvastatin calcium prepared according to by the process of as described in claim 11; and pharmaceutically acceptable ingredients.